Investment opportunity
Game-changing surgical safety system developer with an unassailable recurring revenue model, unsurpassed leadership team, and unprecedented market traction.
INVESTMENT THAT MAKES AN IMPACT
A rapidly growing medical device developer that intends to revolutionize & automate surgical sharps management — while reducing three of the leading causes of operating room distraction
With over $9M invested in technology development, intellectual property protection, and market traction — is offering $10M new capital placement to accredited investors to support final FDA approval, manufacturing, fulfill existing customer demand, expand operations, and broaden the team. The company is poised for execution success with its proven business model, experienced leadership team, and qualified market traction (49 hospitals, 17 ASCs enrolled & 7 ‘Top Ten’ hospital systems engaged).
MAGVATION DEAL SUMMARY
CLASS II MEDICAL DEVICE & Mobile Surgical Platform for sharps safety, staff efficiency, and practice efficacy in the operation room
RAISING $10M to fund FDA 510(k) clearance, system optimization, volume production, US commercialization, and efficacy trials —now that our almost 6-year R&D cycle resulting in validated technology innovations & defensible intellectual property is nearly complete.
49 HOSPITALS & 17 ASCS intend to try the system in 1 operating room for 150 surgeries upon 510(k) approval ~ representing $3.8M in probable revenue conversion & $311M of ARR pipeline potential.
$21M REVENUE PROJECTED for the first full year of completely scaled sales operations, product marketing, and biz-dev in 2025.
EXECUTIVE TEAM with compelling track records of successful execution with 19 exits collectively yielding $11B+ in aggregate returns.
EXTENDED TEAM has 24 surgeons, 21 senior corporate executives, 11 nurses & scrubs, 6 Fortune 500 CXOs, 5 chiefs of surgery, 3 high-ranked military officers, 2 JC execs & 1 former Surgeon General.
SOLID company FOOTING
SOLID BUSINESS MODEL
Per surgery/per sharp operational expense model with 91% ARR
2025 will be Magvation’s first full year of revenue generation operations with a sales target of $21M and >91% ARR at >$10M EBITDA. Projections are calculated based on specific named accounts with well-understood surgical volumes & existing traction. Given the systemically ingrained nature of the safety, efficiency, and liability problems Magvation’s Infrastructure-as-a-Service proposes to solve for hospitals & ASCs, management believes customer switching costs are high and therefore, attrition rates are forecasted at only 5% per annum.
SOLID LEADERSHIP TEAM
$100B+ in past revenue & 19 exits from proven operators
The principals of Magvation have 25+ years of experience, each and collectively generating $100B+ in cumulative revenue — most operating in high-growth MedTech companies, hospital administration, or as practicing surgeons. Jason Howe was one of the ‘sponge-tracking’ industry innovators helping RF Surgical lead the market and to a successful exit in 2015 to Medtronic for $235M. John Friel, the company’s CAO, is acclaimed for operational excellence as CEO of MedRad and orchestrating an exit to Bayer for $11B — which earned him the distinction of being the only person in history to garner two Malcolm Baldridge Awards. Frederick Morrison, the company’s COO, founded Vesta Technologies — which he took to IPO & continued as CEO for eight years until exit.
SOLID MARKET TRACTION
66 distinct accounts already on board
With Jason Howe as the quintessential ‘Selling CEO,’ Magvation has the strategic advantage of a proven hospital account development leader with existing relationships at most leading US healthcare systems, evidenced by an initial $3.8M intent from 49 different hospitals & 17 complementary ASCs (post-510(k) approval). In addition, the company will leverage its 32 surgeon investors & 24 surgeon advisors to quickly generate market penetration, reference accounts, and revenue to hit plan of $482M cumulative revenue in June 2028.
Magvation exists because American’s are unnecessarily at risk every time they undergo a surgical procedure due to completely preventable human & system errors. So, we diligently, systematically, and passionately work to amplify surgical safety, augment surgical processes & advance surgical systems with the goal of elevating Surgical Quality of Care.
We are on an unrelenting mission to make a difference in American lives one surgery at a time — and generate extraordinary returns doing it.
We would love for you to be involved!
